María Isabel González-Tomé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
María Isabel González-Tomé has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Cristina García-Navarro
Infectious Diseases Service, Paed Department, Hospital 12 de Octubre, Madrid, Spain
3 shared publications- Carlos Velo Higueras
Universidad Europea de Valencia, Faculty of Health Sciences, Psychology Department
2 shared publications - Daniel Blázquez-Gamero
Pediatric Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
2 shared publications - Isabel Cuéllar-Flores
Hospital Clinico “San Carlos
2 shared publications José Tomás Ramos
Pediatric Department, Hospital Clínico San Carlos, Madrid, Spain
2 shared publicationsJosé Tomás Ramos-Amador
Department of Pediatrics, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Complutense University of Madrid, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 10 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0218491
Congenital transmission of Chagas disease in a non-endemic area, is an early diagnosis possible?
Chagas disease (CD) is an emergent disease in Europe, due to immigration. The aims of this study are to describe the epidemiological characteristics of a cohort of Chagas infected pregnant women in Spain, to assess the vertical transmission (VT) rate and evaluate the usefulness of the PCR in the diagnosis of congenital infection in the first months of life. A descriptive, retrospective study including Chagas seropositive pregnant women who were attended at three tertiary hospitals in Madrid, from January 2012 to September 2016. Infants were examined by PCR at birth and 1 month later and serologically studied at 9 months or later. Children were considered infected when the parasite was detected by PCR at any age or when serology remained positive without decline over the age of 9 months. We included 122 seropositive-infected pregnant women, 81% were from Bolivia and only 8.2% had been treated before. 125 newborns were studied and finally 109 were included (12.8% lost the follow-up before performing the last serology). The VT rate was 2.75% (95% CI: 0,57–8,8%). Infected infants had positive PCR at birth and 1 month later. All of them were treated successfully with benznidazole (PCR and serology became negative later on). All non-infected children presented negative PCR. The mean age at which uninfected patients had negative serology was 10.5 months. The VT rate is in keeping with literature and confirms the need to carry out a screening in pregnant women coming from endemic areas. PCR seems to be a useful tool to provide early diagnosis of congenital CD.
- 10 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0218491
Open AccessCongenital transmission of Chagas disease in a non-endemic area, is an early diagnosis possible?
Chagas disease (CD) is an emergent disease in Europe, due to immigration. The aims of this study are to describe the epidemiological characteristics of a cohort of Chagas infected pregnant women in Spain, to assess the vertical transmission (VT) rate and evaluate the usefulness of the PCR in the diagnosis of congenital infection in the first months of life. A descriptive, retrospective study including Chagas seropositive pregnant women who were attended at three tertiary hospitals in Madrid, from January 2012 to September 2016. Infants were examined by PCR at birth and 1 month later and serologically studied at 9 months or later. Children were considered infected when the parasite was detected by PCR at any age or when serology remained positive without decline over the age of 9 months. We included 122 seropositive-infected pregnant women, 81% were from Bolivia and only 8.2% had been treated before. 125 newborns were studied and finally 109 were included (12.8% lost the follow-up before performing the last serology). The VT rate was 2.75% (95% CI: 0,57–8,8%). Infected infants had positive PCR at birth and 1 month later. All of them were treated successfully with benznidazole (PCR and serology became negative later on). All non-infected children presented negative PCR. The mean age at which uninfected patients had negative serology was 10.5 months. The VT rate is in keeping with literature and confirms the need to carry out a screening in pregnant women coming from endemic areas. PCR seems to be a useful tool to provide early diagnosis of congenital CD.
- 8 July 2019
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 15 (5) , 492-498
Impact of HIV on the health-related quality of life in youth with perinatally acquired HIV
Studies investigating health-related quality of life (HRQoL) in youth with perinatally acquired HIV (PHIV+) are scarce. This study aimed to compare HRQoL of PHIV+ to sociodemographic-matched youth not living with HIV (HIV−), Spanish general youth population, and to explore associations between sociodemographic variables, drug consumption, and HRQoL.
- 8 July 2019
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 15 (5) , 492-498
Impact of HIV on the health-related quality of life in youth with perinatally acquired HIV
Studies investigating health-related quality of life (HRQoL) in youth with perinatally acquired HIV (PHIV+) are scarce. This study aimed to compare HRQoL of PHIV+ to sociodemographic-matched youth not living with HIV (HIV−), Spanish general youth population, and to explore associations between sociodemographic variables, drug consumption, and HRQoL.
- 13 October 2018
- Published by Georg Thieme Verlag KG in Journal of Pediatric Infectious Diseases
- Vol. 13 (04) , 300-307
Sleep Profile and Self-Reported Neuropsychiatric Symptoms in Vertically HIV-Infected Adolescents on cART
Background Sleep quality (SQ) data in human immunodeficiency virus (HIV) pediatric population are scarce. Our main objective was to assess SQ in our cohort and to determine the impact of antiretroviral therapy (ART) on sleep in a cohort of HIV-infected adolescents on cART. Methods The SQ was assessed through the Pittsburgh Sleep Quality Index (PSQI). Neuropsychiatric symptoms (NS) were recorded using an auto-administered questionnaire. To determine the antiretroviral (ARV) impact of efavirenz (EFV) on SQ, patients on EFV versus protease inhibitors-based regimens were compared. Results Forty-six patients were evaluated (median age: 16 years, interquartile range [IQR]: 10.8, 17)). Age at the start of ART: 1.3 years (0.4, 5.2); 23.9% showed acquired immunodeficiency syndrome (AIDS) category. Median CD4 at baseline was 656 (550, 808) cells/mm3; 91.3% had viral load <50 copies/mL. Median time on cART was 11.3 years (7.5, 15.2). Fifty-two percent of the patients were on EFV-based regimen. No differences were found in clinical and immunovirological variables although patients on EFV were older and were exposed for a longer time to ARV. Poor SQ was found in 26.1% of patients. Most frequent complaints were: sleep disturbances (76.1%), sleep latency (63%), and daytime dysfunction (54.3%). Similarly, there were no significant differences in NS between both treatment groups according to patients' reports but were significantly more common in bad sleepers. Patients on EFV-based regimen were more likely to repeat one or more school grades after the adjustment for age at evaluation and nadir CD4 percentage (odds ratio [OR]: 14.421, confidence interval [CI] 95%: 1.207–172.249, p = 0.035). Conclusions Sleep complaints and NS are common among our cohort of HIV adolescents on long-term cART and interestingly, not only in those who were receiving EFV. Authors declare have no financial relationships relevant to this article to disclose. NeuroCoRISpe project: María Isabel González-Tomé, Pablo Rojo, Daniel Blázquez, Elisa Fernández Cooke, Cristina Epalza, Luis Prieto, Berta Zamora, Cristina García-Navarro, Manuela Martin-Bejarano, Carlos Velo, and Ana Martínez de Aragón (Hospital Doce de Octubre, Madrid); María José Mellado, Luis Escosa, Milagros García Hortelano, and Talía Sainz (Hospital La Paz); José Tomás Ramos and Isabel Cuéllar (Hospital Clínico San Carlos, Madrid); Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús Saavedra, Mar Santos, Ma AngelesMuñoz-Fernández, Beatriz Ruiz-Saez, Carolina Fernandez McPhee, Santiago Jiménez de Ory, Susana Álvarez, and Ignacio Rodriguez Izquierdo (Hospital Gregorio Marañón); Claudia Fortuny and Ton Noguera (Hospital Sant Joan de Deu); David Moreno and Esmeralda Núñez (Hospital Carlos Haya); and Olaf Neth and Dolores Falcón (Hospital Virgen del Rocío). This project is included in CoRISpe Cohort Working Group (AIDS Paed Research network): María José Mellado, Luis Escosa, Milagros García Hortelano, Talía Sainz (Hospital La Paz); María Isabel González-Tomé, Pablo Rojo, Daniel Blázquez, Cristina Epalza (Hospital Doce de Octubre, Madrid); José Tomás Ramos (Hospital Clínico San Carlos, Madrid); Luis Prieto, Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús Saavedra, Mar Santos, Ma Angeles Muñoz, Beatriz Ruiz, Carolina Fernandez McPhee, Santiago Jimenez de Ory, Itzíar Carrasco, (Hospital Gregorio Marañón); Miguel Ángel Roa (Hospital de Móstoles); José Beceiro, María Penín (Hospital Príncipe de Asturias, Alcalá de Henares); Jorge Martínez (Hospital Niño Jesús, Madrid); Katie Badillo (Hospital de Torrejón); Miren Apilanez (Hospital de Donostia, San Sebastián); Itziar Pocheville (Hospital de Cruces, Bilbao); Elisa Garrote (Hospital de Basurto, Bilbao); Elena Colino (Hospital Insular Materno Infantil, Las Palmas de Gran Canaria); Jorge Gómez Sirvent (Hospital Virgen de la Candelaria, Santa Cruz de Tenerife); Mónica Garzón, Vicente Román (Hospital de Lanzarote); María José Muñoz, Raquel Angulo (Hospital de Poniente, El Ejido); Olaf Neth, Lola Falcón (Hospital Virgen del Rocio, Sevilla); Pedro Terol (Hospital Virgen de la Macarena, Sevilla); Juan Luis Santos (Hospital Virgen de las Nieves, Granada); David Moreno (Hospital Carlos Haya, Málaga); Francisco Lendínez (Hospital de Torrecárdenas, Almería); Ana Grande (Complejo Hospitalario Universitario Infanta Cristina, Badajoz); Francisco José Romero (Complejo Hospitalario de Cáceres); Carlos Pérez (Hospital de Cabueñes, Gijón); María Martínez (Hospital Universitario Central de Asturias); Miguel Lillo (Hospital de Albacete); Begoña Losada (Hospital Virgen de la Salud, Toledo); Mercedes Herranz (Hospital Virgen del Camino, Pamplona); Matilde Bustillo, Carmelo Guerrero (Hospital Miguel Servet, Zaragoza); Pilar Collado (Hospital Clínico Lozano Blesa, Zaragoza); José Antonio Couceiro (Complejo Hospitalario de Pontevedra); Leticia Vila (Complejo Hospitalario Universitario La Coruña); Consuelo Calviño (Hospital Universitario Lucus Augusti de Lugo); Ana Isabel Piqueras, Rafael Bretón, Inmaculada Segarra (Hospital La Fe, Valencia); César Gavilán (Hospital San Juan de Alicante); Elena Montesinos (Hospital General de Valencia); Marta Dapena (Hospital de Castellón); Cristina Álvarez, Beatriz Jiménez (Hospital Marqués de Valdecilla, Santander); Ana Gloria Andrés (Hospital de León); Víctor Marugán, Carlos Ochoa (Hospital de Zamora); Santiago Alfayate, Ana Isabel Menasalvas (Hospital Virgen de la Arrixaca, Murcia); Yolanda Ruiz del Prado (Complejo Hospitalario San Millán-San Pedro, Logroño) and Paediatric HIV-BioBank integrated in the Spanish AIDS Research Network and collaborating Centers.
- 13 October 2018
- Published by Georg Thieme Verlag KG in Journal of Pediatric Infectious Diseases
- Vol. 13 (04) , 300-307
Sleep Profile and Self-Reported Neuropsychiatric Symptoms in Vertically HIV-Infected Adolescents on cART
Background Sleep quality (SQ) data in human immunodeficiency virus (HIV) pediatric population are scarce. Our main objective was to assess SQ in our cohort and to determine the impact of antiretroviral therapy (ART) on sleep in a cohort of HIV-infected adolescents on cART. Methods The SQ was assessed through the Pittsburgh Sleep Quality Index (PSQI). Neuropsychiatric symptoms (NS) were recorded using an auto-administered questionnaire. To determine the antiretroviral (ARV) impact of efavirenz (EFV) on SQ, patients on EFV versus protease inhibitors-based regimens were compared. Results Forty-six patients were evaluated (median age: 16 years, interquartile range [IQR]: 10.8, 17)). Age at the start of ART: 1.3 years (0.4, 5.2); 23.9% showed acquired immunodeficiency syndrome (AIDS) category. Median CD4 at baseline was 656 (550, 808) cells/mm3; 91.3% had viral load <50 copies/mL. Median time on cART was 11.3 years (7.5, 15.2). Fifty-two percent of the patients were on EFV-based regimen. No differences were found in clinical and immunovirological variables although patients on EFV were older and were exposed for a longer time to ARV. Poor SQ was found in 26.1% of patients. Most frequent complaints were: sleep disturbances (76.1%), sleep latency (63%), and daytime dysfunction (54.3%). Similarly, there were no significant differences in NS between both treatment groups according to patients' reports but were significantly more common in bad sleepers. Patients on EFV-based regimen were more likely to repeat one or more school grades after the adjustment for age at evaluation and nadir CD4 percentage (odds ratio [OR]: 14.421, confidence interval [CI] 95%: 1.207–172.249, p = 0.035). Conclusions Sleep complaints and NS are common among our cohort of HIV adolescents on long-term cART and interestingly, not only in those who were receiving EFV. Authors declare have no financial relationships relevant to this article to disclose. NeuroCoRISpe project: María Isabel González-Tomé, Pablo Rojo, Daniel Blázquez, Elisa Fernández Cooke, Cristina Epalza, Luis Prieto, Berta Zamora, Cristina García-Navarro, Manuela Martin-Bejarano, Carlos Velo, and Ana Martínez de Aragón (Hospital Doce de Octubre, Madrid); María José Mellado, Luis Escosa, Milagros García Hortelano, and Talía Sainz (Hospital La Paz); José Tomás Ramos and Isabel Cuéllar (Hospital Clínico San Carlos, Madrid); Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús Saavedra, Mar Santos, Ma AngelesMuñoz-Fernández, Beatriz Ruiz-Saez, Carolina Fernandez McPhee, Santiago Jiménez de Ory, Susana Álvarez, and Ignacio Rodriguez Izquierdo (Hospital Gregorio Marañón); Claudia Fortuny and Ton Noguera (Hospital Sant Joan de Deu); David Moreno and Esmeralda Núñez (Hospital Carlos Haya); and Olaf Neth and Dolores Falcón (Hospital Virgen del Rocío). This project is included in CoRISpe Cohort Working Group (AIDS Paed Research network): María José Mellado, Luis Escosa, Milagros García Hortelano, Talía Sainz (Hospital La Paz); María Isabel González-Tomé, Pablo Rojo, Daniel Blázquez, Cristina Epalza (Hospital Doce de Octubre, Madrid); José Tomás Ramos (Hospital Clínico San Carlos, Madrid); Luis Prieto, Sara Guillén (Hospital de Getafe); María Luisa Navarro, Jesús Saavedra, Mar Santos, Ma Angeles Muñoz, Beatriz Ruiz, Carolina Fernandez McPhee, Santiago Jimenez de Ory, Itzíar Carrasco, (Hospital Gregorio Marañón); Miguel Ángel Roa (Hospital de Móstoles); José Beceiro, María Penín (Hospital Príncipe de Asturias, Alcalá de Henares); Jorge Martínez (Hospital Niño Jesús, Madrid); Katie Badillo (Hospital de Torrejón); Miren Apilanez (Hospital de Donostia, San Sebastián); Itziar Pocheville (Hospital de Cruces, Bilbao); Elisa Garrote (Hospital de Basurto, Bilbao); Elena Colino (Hospital Insular Materno Infantil, Las Palmas de Gran Canaria); Jorge Gómez Sirvent (Hospital Virgen de la Candelaria, Santa Cruz de Tenerife); Mónica Garzón, Vicente Román (Hospital de Lanzarote); María José Muñoz, Raquel Angulo (Hospital de Poniente, El Ejido); Olaf Neth, Lola Falcón (Hospital Virgen del Rocio, Sevilla); Pedro Terol (Hospital Virgen de la Macarena, Sevilla); Juan Luis Santos (Hospital Virgen de las Nieves, Granada); David Moreno (Hospital Carlos Haya, Málaga); Francisco Lendínez (Hospital de Torrecárdenas, Almería); Ana Grande (Complejo Hospitalario Universitario Infanta Cristina, Badajoz); Francisco José Romero (Complejo Hospitalario de Cáceres); Carlos Pérez (Hospital de Cabueñes, Gijón); María Martínez (Hospital Universitario Central de Asturias); Miguel Lillo (Hospital de Albacete); Begoña Losada (Hospital Virgen de la Salud, Toledo); Mercedes Herranz (Hospital Virgen del Camino, Pamplona); Matilde Bustillo, Carmelo Guerrero (Hospital Miguel Servet, Zaragoza); Pilar Collado (Hospital Clínico Lozano Blesa, Zaragoza); José Antonio Couceiro (Complejo Hospitalario de Pontevedra); Leticia Vila (Complejo Hospitalario Universitario La Coruña); Consuelo Calviño (Hospital Universitario Lucus Augusti de Lugo); Ana Isabel Piqueras, Rafael Bretón, Inmaculada Segarra (Hospital La Fe, Valencia); César Gavilán (Hospital San Juan de Alicante); Elena Montesinos (Hospital General de Valencia); Marta Dapena (Hospital de Castellón); Cristina Álvarez, Beatriz Jiménez (Hospital Marqués de Valdecilla, Santander); Ana Gloria Andrés (Hospital de León); Víctor Marugán, Carlos Ochoa (Hospital de Zamora); Santiago Alfayate, Ana Isabel Menasalvas (Hospital Virgen de la Arrixaca, Murcia); Yolanda Ruiz del Prado (Complejo Hospitalario San Millán-San Pedro, Logroño) and Paediatric HIV-BioBank integrated in the Spanish AIDS Research Network and collaborating Centers.
- Open Access
- 1 March 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 88 (3) , 119-121
Luces y sombras en la transmisión vertical de la enfermedad de Chagas
- 1 March 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 88 (3) , 119-121
Open AccessLuces y sombras en la transmisión vertical de la enfermedad de Chagas
- Open Access
- 1 March 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 88 (3) , 119-121
Challenges and opportunities in the vertical transmission of Chagas disease
- 1 March 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 88 (3) , 119-121
Open AccessChallenges and opportunities in the vertical transmission of Chagas disease
- Open Access
- 8 March 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-7
Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults
Successful antiretroviral therapy (ART) has dramatically reduced mortality among HIV-infected children. However, there is growing concern about long-term effects associated to ART. The aim of this study was to determine the prevalence of metabolic abnormalities in a cohort of perinatally HIV-infected adolescents and young adults and to identify associated factors. We present results from a cross-sectional analysis including individuals 12 to 20 years of age, from a prospective, longitudinal cohort of perinatally-acquired HIV-infected children, adolescents and young adults in Madrid. Clinical and immunological data were recorded and complete lipid and glycemic profiles were determined. Ninety-nine adolescents were included, with a median age of 15.3 years [13.6-16.7]. Patients with abnormal levels of lipids were as follows: 27.2% total cholesterol ≥200 mg/dl, 25.9% LDL cholesterol (LDL-c) ≥ 130 mg/dl, 14.1% HDL-C < 35 mg/dl and 39.8% triglycerides ≥ 150 mg/dl. Current use of protease inhibitors (PI) was associated with higher triglyceride values (p = 0.022). Four (4.6%) patients showed fasting glucose ≥ 100 mg/dl and 30.6% presented with insulin resistance (IR) (HOMA-IR over the 90th centile). In the multivariate logistic regression analysis adjusted for sex, age, weight, Tanner stage, protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI) treatment length and CD4 nadir, IR was associated with higher waist circumference Z score; OR: 3.92(CI95%: 1.15-13.4) (p = 0.03). There was a high prevalence of insulin resistance and lipid abnormalities in this cohort of perinatally-acquired HIV-infected adolescents. A simple clinical measurement like waist circumference Z score might be a reliable marker and predictor of insulin resistance in these patients.
- 8 March 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-7
Open AccessLipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults
Successful antiretroviral therapy (ART) has dramatically reduced mortality among HIV-infected children. However, there is growing concern about long-term effects associated to ART. The aim of this study was to determine the prevalence of metabolic abnormalities in a cohort of perinatally HIV-infected adolescents and young adults and to identify associated factors. We present results from a cross-sectional analysis including individuals 12 to 20 years of age, from a prospective, longitudinal cohort of perinatally-acquired HIV-infected children, adolescents and young adults in Madrid. Clinical and immunological data were recorded and complete lipid and glycemic profiles were determined. Ninety-nine adolescents were included, with a median age of 15.3 years [13.6-16.7]. Patients with abnormal levels of lipids were as follows: 27.2% total cholesterol ≥200 mg/dl, 25.9% LDL cholesterol (LDL-c) ≥ 130 mg/dl, 14.1% HDL-C < 35 mg/dl and 39.8% triglycerides ≥ 150 mg/dl. Current use of protease inhibitors (PI) was associated with higher triglyceride values (p = 0.022). Four (4.6%) patients showed fasting glucose ≥ 100 mg/dl and 30.6% presented with insulin resistance (IR) (HOMA-IR over the 90th centile). In the multivariate logistic regression analysis adjusted for sex, age, weight, Tanner stage, protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI) treatment length and CD4 nadir, IR was associated with higher waist circumference Z score; OR: 3.92(CI95%: 1.15-13.4) (p = 0.03). There was a high prevalence of insulin resistance and lipid abnormalities in this cohort of perinatally-acquired HIV-infected adolescents. A simple clinical measurement like waist circumference Z score might be a reliable marker and predictor of insulin resistance in these patients.
- Open Access
- 24 December 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 700
Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009
Antiretroviral therapy (ART) in pregnancy has resulted in a marked impact on reducing the risk of mother-to-child transmission (MCT) of HIV. However the safety of in utero ART exposure in newborns remains a concern. A multicenter prospective observational study of HIV-infected mother and their infants was performed in Madrid, Spain, from 2000 to 2009. Children had regular visits with clinical examination according to protocol until the age of 24 months. An abdominal ultrasound and an echocardiogram were scheduled during follow up. Birth defects (BDs) were registered according to European Surveillance of Congenital Anomalies (EUROCAT). A total of 897 live births from 872 mothers were included. Overall the birth defects prevalence observed was 6.9% (95% CI 5.4-9.1).The most commonly reported birth defects types were in genital organs and urinary system (19 cases, 30.6%) and cardiovascular system (17 cases, 27.4%). There was no increased risk for infants exposed in the first trimester to ARVs compared with unexposed infants. No significant associations were observed between exposure to any individual antiretroviral agent during pregnancy and birth defects A higher prevalence of BDs was observed, higher than previously reported. In utero exposure to ART was not proved to be a major risk factor of birth defects in infants. However the relatively small number of patients is a major limitation of this study.
- 24 December 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 700
Open AccessBirth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009
Antiretroviral therapy (ART) in pregnancy has resulted in a marked impact on reducing the risk of mother-to-child transmission (MCT) of HIV. However the safety of in utero ART exposure in newborns remains a concern. A multicenter prospective observational study of HIV-infected mother and their infants was performed in Madrid, Spain, from 2000 to 2009. Children had regular visits with clinical examination according to protocol until the age of 24 months. An abdominal ultrasound and an echocardiogram were scheduled during follow up. Birth defects (BDs) were registered according to European Surveillance of Congenital Anomalies (EUROCAT). A total of 897 live births from 872 mothers were included. Overall the birth defects prevalence observed was 6.9% (95% CI 5.4-9.1).The most commonly reported birth defects types were in genital organs and urinary system (19 cases, 30.6%) and cardiovascular system (17 cases, 27.4%). There was no increased risk for infants exposed in the first trimester to ARVs compared with unexposed infants. No significant associations were observed between exposure to any individual antiretroviral agent during pregnancy and birth defects A higher prevalence of BDs was observed, higher than previously reported. In utero exposure to ART was not proved to be a major risk factor of birth defects in infants. However the relatively small number of patients is a major limitation of this study.
- 1 December 2014
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 32 (10) , 631-637
Aspectos psicosociales en una cohorte de adolescentes con infección por el virus de la inmunodeficiencia humana por transmisión vertical. NeuroCoRISpeS
- 1 December 2014
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 32 (10) , 631-637
Aspectos psicosociales en una cohorte de adolescentes con infección por el virus de la inmunodeficiencia humana por transmisión vertical. NeuroCoRISpeS
- 1 October 2013
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 31 (8) , 535-542
Recomendaciones para el diagnóstico, seguimiento y tratamiento de la embarazada y del niño con enfermedad de Chagas
- 1 October 2013
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 31 (8) , 535-542
Recomendaciones para el diagnóstico, seguimiento y tratamiento de la embarazada y del niño con enfermedad de Chagas
- Open Access
- 27 October 2008
- Published by Wiley in HIV Medicine
- Vol. 9 (10) , 868-874
Gestational diabetes mellitus in a cohort of HIV‐1 infected women
Objectives: We undertook a prospective study to estimate the prevalence of gestational diabetes mellitus (GDM) and associated risk factors in a cohort of 669 HIV‐1 infected women.Methods: The O'Sullivan and glucose tolerance tests were performed during regular visits of 609 mothers.Results: The median age of the cohort was 30.7 years (range 16–44), with most women having had heterosexual contact (67%). The majority were in Centers for Disease Control (CDC) category A (71%) and 53% exhibited hepatitis C co‐infection. Median viral load and CD4 count at third trimester were 545 cells/μL (range 139–1690 cells/μL) and 1.9 log (range 1.7–5.4), respectively. Seventy‐four per cent of the patients were treated with highly active antiretroviral therapy (HAART), of whom 41% received a protease inhibitor (PI). An above‐average prevalence of 7% [95% confidence interval (CI) 5.2–9.5] for positive GDM diagnosis was found. Risk factors associated with GDM in univariate analysis included older age, hepatitis C co‐infection, stavudine and PI exposure. However, only older age [adjusted odds ratio (AOR) 1.09, 95% CI 1–1.1] and PI exposure (AOR 2.4, 95% CI 1–5.3) remained as independent risk factors for GDM development in multivariate analysis.Conclusions: In our cohort, the prevalence of GDM appears to be increased, with older age and PI exposure contributing as significant independent risk factors.
- 27 October 2008
- Published by Wiley in HIV Medicine
- Vol. 9 (10) , 868-874
Open AccessGestational diabetes mellitus in a cohort of HIV‐1 infected women
Objectives: We undertook a prospective study to estimate the prevalence of gestational diabetes mellitus (GDM) and associated risk factors in a cohort of 669 HIV‐1 infected women.Methods: The O'Sullivan and glucose tolerance tests were performed during regular visits of 609 mothers.Results: The median age of the cohort was 30.7 years (range 16–44), with most women having had heterosexual contact (67%). The majority were in Centers for Disease Control (CDC) category A (71%) and 53% exhibited hepatitis C co‐infection. Median viral load and CD4 count at third trimester were 545 cells/μL (range 139–1690 cells/μL) and 1.9 log (range 1.7–5.4), respectively. Seventy‐four per cent of the patients were treated with highly active antiretroviral therapy (HAART), of whom 41% received a protease inhibitor (PI). An above‐average prevalence of 7% [95% confidence interval (CI) 5.2–9.5] for positive GDM diagnosis was found. Risk factors associated with GDM in univariate analysis included older age, hepatitis C co‐infection, stavudine and PI exposure. However, only older age [adjusted odds ratio (AOR) 1.09, 95% CI 1–1.1] and PI exposure (AOR 2.4, 95% CI 1–5.3) remained as independent risk factors for GDM development in multivariate analysis.Conclusions: In our cohort, the prevalence of GDM appears to be increased, with older age and PI exposure contributing as significant independent risk factors.